Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by First Turn Management LLC

First Turn Management LLC grew its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 10.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 621,306 shares of the biotechnology company’s stock after acquiring an additional 60,317 shares during the quarter. First Turn Management LLC owned about 0.68% of Rocket Pharmaceuticals worth $11,476,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of RCKT. Janus Henderson Group PLC increased its stake in shares of Rocket Pharmaceuticals by 174.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,606,016 shares of the biotechnology company’s stock valued at $70,170,000 after acquiring an additional 1,656,111 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Rocket Pharmaceuticals by 11.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,943,160 shares of the biotechnology company’s stock worth $79,290,000 after purchasing an additional 314,086 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Rocket Pharmaceuticals during the 2nd quarter worth about $2,144,000. Harbor Capital Advisors Inc. grew its holdings in shares of Rocket Pharmaceuticals by 73.5% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 168,506 shares of the biotechnology company’s stock worth $3,112,000 after purchasing an additional 71,372 shares during the period. Finally, EFG Asset Management North America Corp. grew its holdings in shares of Rocket Pharmaceuticals by 47.0% during the 2nd quarter. EFG Asset Management North America Corp. now owns 222,046 shares of the biotechnology company’s stock worth $4,780,000 after purchasing an additional 71,044 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Down 2.3 %

RCKT stock opened at $13.66 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals, Inc. has a 12-month low of $13.39 and a 12-month high of $32.53. The stock’s 50 day simple moving average is $17.63 and its 200 day simple moving average is $20.10.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RCKT. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Scotiabank began coverage on Rocket Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price target for the company. JPMorgan Chase & Co. upped their price target on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Canaccord Genuity Group restated a “buy” rating and issued a $38.00 price target on shares of Rocket Pharmaceuticals in a report on Monday, September 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $52.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.